1. A method of modulating the function and / or expression of a sirtuin polynucleotide (SIRT) selected from the group consisting of SIRTs 2, 3, 4, 5, and 7 in cells or tissues of a patient in vivo or in vitro, comprising: bringing said cells or tissues into contact with at least one antisense oligonucleotide comprising in length from 5 to 30 nucleotides, said at least one oligonucleotide having a sequence of at least 50% identical to the sequence inversely complementary to a polynucleotide containing from 5 to 30 consecutive nucleotides eotides in the range from 1 to 726 nucleotides of the sequence SEQ ID NO: 17, from 1 to 320 nucleotides of the sequence SEQ ID NO: 18, from 1 to 616 nucleotides of the sequence SEQ ID NO: 19, from 1 to 492 nucleotides of the sequence SEQ ID NO: 20 or from 1 to 705 nucleotides of the sequence SEQ ID NO: 23, or from 1 to 2714 nucleotides of the sequence SEQ ID NO: 141, or from 1 to 1757 nucleotides of the sequence SEQ ID NO: 142, or from 1 to 3647 nucleotides of the sequence SEQ ID NO : 143； thereby modulating the function and / or expression of said sirtuin polynucleotide (SIRT) in cells or tissues of a patient in vivo or in vitro. 2. The method according to claim 1, characterized in that said cells or tissues are the target of more than one antisense oligonucleotide aimed at overlapping and / or non-overlapping sequences of sirtuin polynucleotide (SIRT). A method according to any one of claims 1 and 2, characterized in that said at least one antisense oligonucleotide contains one or more modifications selected from the following: at least one modified sugar fragment, at least one modified internucleoside binding1. Способ модулирования функции и/или экспрессии полинуклеотида сиртуина (SIRT), выбранного из группы, состоящей из SIRT 2, 3, 4, 5 и 7 в клетках или тканях пациента in vivo или in vitro, включающий:приведение указанных клеток или тканей в контакт с по меньшей мере одним антисмысловым олигонуклеотидом, составляющим в длину от
